The launch follows research published in the Journal of Urology that found MPS2 delivers market-leading accuracy in predicting the risk of clinically significant prostate cancer even without conducting a digital rectal exam (DRE) before collecting a urine sample.

“Giving patients the option to take the test at home, without the need to schedule a visit to the doctor or have a DRE, adds convenience, removes stigma and broadens access to a powerful method of screening for a serious disease,” said Spencer Heaton, Chief Medical Officer at Lynx Dx. “MyProstateScore 2.0 offers more clarity about the need for a biopsy in a way that aligns seamlessly with modern clinical workflows.”

The study in Journal of Urology, found that MPS2 significantly outperformed traditional prostate-specific antigen (PSA) testing by identifying up to 53% of men whose biopsy would be negative while maintaining 91–94% sensitivity for high-grade cancer (Grade Group ≥2). While PSA testing remains the gold standard of prostate cancer screening, the test provides an incomplete picture and results in overutilization of prostate biopsies, three-quarters of which come back negative for clinically significant prostate cancer.